SG11202011886TA - PHARMACEUTICAL COMBINATION, COMPOSITION AND FORMULATION CONTAINING GLUCOKINASE ACTIVATOR AND a-GLUCOSIDASE INHIBITOR, PREPARATION METHODS THEREFOR AND USES THEREOF - Google Patents

PHARMACEUTICAL COMBINATION, COMPOSITION AND FORMULATION CONTAINING GLUCOKINASE ACTIVATOR AND a-GLUCOSIDASE INHIBITOR, PREPARATION METHODS THEREFOR AND USES THEREOF

Info

Publication number: SG11202011886TA
Authority: SG; Singapore
Prior art keywords: composition; preparation methods; formulation containing; pharmaceutical combination; glucosidase inhibitor
Prior art date: 2018-05-31

Application number

SG11202011886TA

Inventor

Li Chen

Yongguo Li

Gaosen Wang

Huisheng Gao

Original Assignee

Hua Medicine Shanghai Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2018-05-31

Filing date

2019-05-28

Publication date

2020-12-30

2019-05-28 Application filed by Hua Medicine Shanghai Ltd filed Critical Hua Medicine Shanghai Ltd

2020-12-30 Publication of SG11202011886TA publication Critical patent/SG11202011886TA/en

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/133—Amines having hydroxy groups, e.g. sphingosine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/382—Heterocyclic compounds having sulfur as a ring hetero atom having six-membered rings, e.g. thioxanthenes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/4035—Isoindoles, e.g. phthalimide
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/7036—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1611—Inorganic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
- A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2813—Inorganic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/38—Nitrogen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Organic Chemistry (AREA)
Diabetes (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Obesity (AREA)
Hematology (AREA)
Endocrinology (AREA)
Emergency Medicine (AREA)
Molecular Biology (AREA)
Inorganic Chemistry (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Child & Adolescent Psychology (AREA)
Hospice & Palliative Care (AREA)
Psychiatry (AREA)
Gastroenterology & Hepatology (AREA)
Biophysics (AREA)
Urology & Nephrology (AREA)
Vascular Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Plural Heterocyclic Compounds (AREA)

SG11202011886TA 2018-05-31 2019-05-28 PHARMACEUTICAL COMBINATION, COMPOSITION AND FORMULATION CONTAINING GLUCOKINASE ACTIVATOR AND a-GLUCOSIDASE INHIBITOR, PREPARATION METHODS THEREFOR AND USES THEREOF SG11202011886TA (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
CN201810556685		2018-05-31
PCT/CN2019/088865 WO2019228366A1 (en)	2018-05-31	2019-05-28	PHARMACEUTICAL COMBINATION, COMPOSITION AND FORMULATION CONTAINING GLUCOKINASE ACTIVATOR AND α-GLUCOSIDASE INHIBITOR, PREPARATION METHODS THEREFOR AND USES THEREOF

Publications (1)

Publication Number	Publication Date
SG11202011886TA true SG11202011886TA (en)	2020-12-30

Family

ID=68697184

Family Applications (6)

Application Number	Title	Priority Date	Filing Date
SG11202011893UA SG11202011893UA (en)	2018-05-31	2019-05-28	Pharmaceutical combination and composition, and combination preparation containing glucokinase activator and biguanide hypoglycemic drug as well as preparation method and use thereof
SG11202011883RA SG11202011883RA (en)	2018-05-31	2019-05-28	Pharmaceutical combination, composition, and combination formulation containing glucokinase activator and ppar receptor activator, and preparation methods and uses thereof
SG11202011881PA SG11202011881PA (en)	2018-05-31	2019-05-28	Pharmaceutical combination, composition and combination formulation comprising glucokinase activator and dpp-iv inhibitor, and preparation method and use thereof
SG11202011888VA SG11202011888VA (en)	2018-05-31	2019-05-28	Pharmaceutical combination, composition and compound preparation containing glucokinase activator and k-atp channel blocker, preparation method therefor and use thereof
SG11202011884QA SG11202011884QA (en)	2018-05-31	2019-05-28	Pharmaceutical combination, composition, and combination preparation comprising glucokinase activator and sglt-2 inhibitor and preparation methods and uses thereof
SG11202011886TA SG11202011886TA (en)	2018-05-31	2019-05-28	PHARMACEUTICAL COMBINATION, COMPOSITION AND FORMULATION CONTAINING GLUCOKINASE ACTIVATOR AND a-GLUCOSIDASE INHIBITOR, PREPARATION METHODS THEREFOR AND USES THEREOF

Family Applications Before (5)

Application Number	Title	Priority Date	Filing Date
SG11202011893UA SG11202011893UA (en)	2018-05-31	2019-05-28	Pharmaceutical combination and composition, and combination preparation containing glucokinase activator and biguanide hypoglycemic drug as well as preparation method and use thereof
SG11202011883RA SG11202011883RA (en)	2018-05-31	2019-05-28	Pharmaceutical combination, composition, and combination formulation containing glucokinase activator and ppar receptor activator, and preparation methods and uses thereof
SG11202011881PA SG11202011881PA (en)	2018-05-31	2019-05-28	Pharmaceutical combination, composition and combination formulation comprising glucokinase activator and dpp-iv inhibitor, and preparation method and use thereof
SG11202011888VA SG11202011888VA (en)	2018-05-31	2019-05-28	Pharmaceutical combination, composition and compound preparation containing glucokinase activator and k-atp channel blocker, preparation method therefor and use thereof
SG11202011884QA SG11202011884QA (en)	2018-05-31	2019-05-28	Pharmaceutical combination, composition, and combination preparation comprising glucokinase activator and sglt-2 inhibitor and preparation methods and uses thereof

Country Status (26)

Country	Link
US (8)	US12318366B2 (en)
EP (6)	EP3804715B1 (en)
JP (12)	JP7565589B2 (en)
KR (7)	KR102695135B1 (en)
CN (12)	CN110548027B (en)
AU (6)	AU2019278013B2 (en)
BR (6)	BR112020024125A2 (en)
CA (6)	CA3101822C (en)
DK (3)	DK3804716T3 (en)
ES (3)	ES3016532T3 (en)
FI (3)	FI3804716T3 (en)
HR (3)	HRP20250258T1 (en)
HU (3)	HUE070296T2 (en)
IL (6)	IL279035B2 (en)
LT (3)	LT3804716T (en)
MX (6)	MX2020012969A (en)
PL (3)	PL3804714T3 (en)
PT (3)	PT3804716T (en)
RS (3)	RS66565B1 (en)
RU (1)	RU2770775C1 (en)
SG (6)	SG11202011893UA (en)
SI (3)	SI3804715T1 (en)
SM (3)	SMT202500107T1 (en)
TW (6)	TWI764000B (en)
WO (6)	WO2019228365A1 (en)
ZA (6)	ZA202007679B (en)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU2020426356A1 (en) *	2020-01-31	2022-08-25	Hua Medicine (Shanghai) Ltd.	Treating treatment-resistant diabetes with glucokinase activator
US11872221B2 (en)	2020-01-31	2024-01-16	Hua Medicine (Shanghai) Ltd.	Treating untreated or treatment-resistant diabetes with glucokinase activator
US11813274B2 (en)	2020-04-22	2023-11-14	Hua Medicine (Shanghai) Ltd.	Treating untreated or treatment-resistant diabetes with glucokinase activator and sodium-glucose cotransporter-2 inhibitor
CA3181882A1 (en) *	2020-04-22	2021-10-28	Hua Medicine (Shanghai) Ltd.	Treating untreated or treatment-resistant diabetes with glucokinase activator and sodium-glucose cotransporter-2 inhibitor
AU2020451588A1 (en) *	2020-06-04	2023-01-19	Hua Medicine (Shanghai) Ltd.	Glucokinase activator for treating diabetes with renal impairment
US11857536B2 (en)	2020-06-04	2024-01-02	Hua Medicine (Shanghai) Ltd.	Glucokinase activator for treating diabetes with renal impairment
AU2020451966A1 (en) *	2020-06-04	2023-01-19	Hua Medicine (Shanghai) Ltd.	Glucokinase activator for treating diabetes with hepatic impairment
CN111759838B (en) *	2020-07-02	2022-01-25	深圳微芯生物科技股份有限公司	Pharmaceutical composition of pharmaceutically acceptable salt of sitagliptin and application thereof
CN112206216B (en) *	2020-10-15	2023-03-17	江西华士药业有限公司	Preparation method of sustained-release dapagliflozin
WO2022104621A1 (en) *	2020-11-19	2022-05-27	北京睿创康泰医药研究院有限公司	Fixed-dose combination of sglt-2 inhibitor and angiotensin converting enzyme inhibitor, and use thereof
CN116887866A (en)	2020-12-03	2023-10-13	巴特尔纪念研究院	Polymer nanoparticle and DNA nanostructure compositions and methods for non-viral delivery
CN113527265B9 (en) *	2021-02-02	2022-07-19	湖南南新制药股份有限公司	Deuterated pyrrolidone derivative, pharmaceutical composition and application thereof
US12031128B2 (en)	2021-04-07	2024-07-09	Battelle Memorial Institute	Rapid design, build, test, and learn technologies for identifying and using non-viral carriers
CN113750100B (en) *	2021-08-31	2022-12-30	海南中济医药科技有限公司	Pharmaceutical composition containing polyagliflozin Ai Ting and sitagliptin and preparation method thereof
AR127064A1 (en) *	2021-09-15	2023-12-13	Hua Medicine Shanghai Ltd	PRODRUGS OF PYRROLIDONE DERIVATIVES AS A GLUCOKINASE ACTIVATOR
WO2024005755A1 (en) *	2022-06-29	2024-01-04	Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi	A tablet comprising empagliflozin
CN115598234B (en) *	2022-09-06	2025-05-30	株洲千金药业股份有限公司	A method for detecting enantiomers of linagliptin and its application
AR132113A1 (en) *	2023-03-13	2025-05-28	Hua Medicine Shanghai Ltd	SOLID FORM OF PYRROLIDONE DERIVATIVES AS GLUCOKINASE ACTIVATOR
WO2024214117A2 (en) *	2023-04-11	2024-10-17	Peptris Technologies Private Limited	Compounds for upregulating utrophin levels in muscle cells and method of application thereof
WO2024251159A1 (en) *	2023-06-06	2024-12-12	华领医药技术（上海）有限公司	Glucokinase activator for cognitive disorders and neurodegenerative diseases
US20250195440A1 (en) *	2023-12-14	2025-06-19	Hua Medicine USA Inc.	Pharmaceutical formulation comprising glucokinase activator and use thereof

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB9511220D0 (en) *	1995-06-02	1995-07-26	Glaxo Group Ltd	Solid dispersions
US20040081697A1 (en) *	1998-11-12	2004-04-29	Smithkline Beecham P.L.C.	Pharmaceutical composition for modified release of an insulin sensitiser and another antidiabetic agent
ITFI20010230A1 (en)	2001-11-29	2003-05-29	Menarini Int Operations Lu Sa	PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF TYPE II DIABETES
EP1701735A4 (en)	2003-10-27	2009-12-09	Innodia Inc	Use of hydroxylated amino acids for treating diabetes
KR100952090B1 (en)	2003-10-31	2010-04-13	다케다 야쿠힌 고교 가부시키가이샤	Solid preparations containing insulin sensitizers, insulin secretagogues and polyoxyethylene sorbitan fatty acid esters
US7687502B2 (en)	2004-03-23	2010-03-30	Banyu Pharmaceutical Co., Ltd.	Substituted quinazoline or pyridopyrimidine derivative
BRPI0609464A2 (en)	2005-05-23	2010-04-13	Japan Tobacco Inc	pyrazole compound and therapeutic agent for diabetes comprising the same
PE20080251A1 (en)	2006-05-04	2008-04-25	Boehringer Ingelheim Int	USES OF DPP IV INHIBITORS
US7910747B2 (en) *	2006-07-06	2011-03-22	Bristol-Myers Squibb Company	Phosphonate and phosphinate pyrazolylamide glucokinase activators
US20080107725A1 (en) *	2006-10-13	2008-05-08	Albano Antonio A	Pharmaceutical Solid Dosage Forms Comprising Amorphous Compounds Micro-Embedded in Ionic Water-Insoluble Polymers
AR063627A1 (en)	2006-11-09	2009-02-04	Boehringer Ingelheim Int	COMBINED THERAPY WITH SGL INHIBITORS T-2 AND ITS PHARMACEUTICAL COMPOSITIONS
HRP20120814T1 (en) *	2007-09-21	2012-11-30	Array Biopharma, Inc.	Pyridine-1,2,4-thiadiazole derivatives as glucocinase activators for the treatment of melitic diabetes
US7741327B2 (en) *	2008-04-16	2010-06-22	Hoffmann-La Roche Inc.	Pyrrolidinone glucokinase activators
US8563730B2 (en)	2008-05-16	2013-10-22	Takeda San Diego, Inc.	Pyrazole and fused pyrazole glucokinase activators
TWI492943B (en)	2008-12-05	2015-07-21	大塚製藥股份有限公司	Quinolone compound and pharmaceutical composition
MA33071B1 (en)	2009-01-30	2012-02-01	Takeda Pharmaceutical	Composite of intensive nucleus and its use
CN117547538A (en)	2009-02-13	2024-02-13	勃林格殷格翰国际有限公司	Antidiabetic drugs containing a DPP-4 inhibitor (linagliptin) optionally in combination with other antidiabetic drugs
KR101295937B1 (en) *	2009-03-11	2013-08-14	화이자 인코포레이티드	Benzofuranyl derivatives used as glucokinase inhibitors
WO2010107610A1 (en)	2009-03-17	2010-09-23	Merck Sharp & Dohme Corp.	Method for treatment of diabetes and related conditions with combination therapy and compositions containing such compounds
US8685934B2 (en)	2009-05-27	2014-04-01	Bristol-Myers Squibb Company	Methods for treating extreme insulin resistance in patients resistant to previous treatment with other anti-diabetic drugs employing an SGLT2 inhibitor and compositions thereof
RU2558798C2 (en) *	2009-11-13	2015-08-10	Астразенека Аб	Compositions of pill with immediate release
MX2012005425A (en) *	2009-11-13	2012-06-14	Astrazeneca Uk Ltd	Reduced mass metformin formulations.
US9359313B2 (en)	2010-05-26	2016-06-07	Vtv Therapeutics Llc	Use of metformin in combination with a glucokinase activator and compositions comprising metformin and a glucokinase activator
CN102558167A (en)	2010-12-29	2012-07-11	中国医学科学院药物研究所	Thiazolidine derivant with GK and PPAR double excitation activity
ES2448398T3 (en)	2011-06-03	2014-03-13	Ratiopharm Gmbh	Pharmaceutical composition comprising dapagliflozin and cyclodextrin
JP6234443B2 (en) *	2012-05-17	2017-11-22	ブイティーブイ・セラピューティクス・エルエルシー	Glucokinase activator composition for the treatment of diabetes
RU2662157C2 (en)	2012-11-13	2018-07-24	Ниссан Кемикал Индастриз, Лтд.	2-pyridone compound
TW201446286A (en) *	2013-01-31	2014-12-16	Gilead Pharmasset Llc	Solid dispersion formulation of an antiviral compound
CA2812519A1 (en)	2013-04-05	2014-10-05	Boehringer Ingelheim International Gmbh	Pharmaceutical composition, methods for treating and uses thereof
CN104208034B (en) *	2013-12-11	2017-11-07	重庆康刻尔制药有限公司	A kind of Glimepiride medicinal composition tablets, preparation method and applications
CN103655539B (en)	2013-12-13	2019-09-13	重庆医药工业研究院有限责任公司	A kind of oral solid formulation of canagliflozin and preparation method thereof
CN104840960A (en) *	2014-02-14	2015-08-19	广东东阳光药业有限公司	Antidiabetic pharmaceutical composition and preparation method thereof
AR099936A1 (en) *	2014-04-04	2016-08-31	Sanofi Sa	CONDENSED HETEROCICLES REPLACED AS MODULATORS OF GPR119 FOR THE TREATMENT OF DIABETES, OBESITY, DISLIPIDEMIA AND RELATED DISORDERS
WO2015176267A1 (en)	2014-05-22	2015-11-26	Merck Sharp & Dohme Corp.	Antidiabetic tricyclic compounds
WO2017083925A1 (en)	2015-11-19	2017-05-26	Garvan Institute Of Medical Research	Compounds and methods for treating metabolic disorders
US20190070120A1 (en)	2016-03-10	2019-03-07	Aurobindo Pharma Ltd.	Pharmaceutical Composition Comprising Canagliflozin, Process of Preparation and Use Thereof
CN106474480A (en)	2016-11-15	2017-03-08	深圳奥萨医疗有限公司	Medical composition and its use containing glucokinase activator and B family vitamin
CN115715762A (en) *	2016-12-15	2023-02-28	华领医药技术（上海）有限公司	Oral preparation of glucokinase activator and preparation method thereof

2019
- 2019-05-28 FI FIEP19811691.5T patent/FI3804716T3/en active
- 2019-05-28 DK DK19811691.5T patent/DK3804716T3/en active
- 2019-05-28 HU HUE19810783A patent/HUE070296T2/en unknown
- 2019-05-28 SG SG11202011893UA patent/SG11202011893UA/en unknown
- 2019-05-28 BR BR112020024125-3A patent/BR112020024125A2/en unknown
- 2019-05-28 IL IL279035A patent/IL279035B2/en unknown
- 2019-05-28 WO PCT/CN2019/088864 patent/WO2019228365A1/en active Application Filing
- 2019-05-28 BR BR112020024348-5A patent/BR112020024348A2/en unknown
- 2019-05-28 KR KR1020207037560A patent/KR102695135B1/en active Active
- 2019-05-28 SG SG11202011883RA patent/SG11202011883RA/en unknown
- 2019-05-28 EP EP19811377.1A patent/EP3804715B1/en active Active
- 2019-05-28 CN CN201910453724.4A patent/CN110548027B/en active Active
- 2019-05-28 CA CA3101822A patent/CA3101822C/en active Active
- 2019-05-28 CN CN201910453726.3A patent/CN110548149B/en active Active
- 2019-05-28 MX MX2020012969A patent/MX2020012969A/en unknown
- 2019-05-28 BR BR112020024269-1A patent/BR112020024269A2/en unknown
- 2019-05-28 WO PCT/CN2019/088865 patent/WO2019228366A1/en not_active Application Discontinuation
- 2019-05-28 EP EP19810441.6A patent/EP3804713A4/en active Pending
- 2019-05-28 CN CN201910453725.9A patent/CN110548148B/en active Active
- 2019-05-28 KR KR1020207037957A patent/KR20210016437A/en not_active Ceased
- 2019-05-28 SG SG11202011881PA patent/SG11202011881PA/en unknown
- 2019-05-28 BR BR112020024107-5A patent/BR112020024107A2/en unknown
- 2019-05-28 SG SG11202011888VA patent/SG11202011888VA/en unknown
- 2019-05-28 SI SI201930906T patent/SI3804715T1/en unknown
- 2019-05-28 HR HRP20250258TT patent/HRP20250258T1/en unknown
- 2019-05-28 LT LTEPPCT/CN2019/088863T patent/LT3804716T/en unknown
- 2019-05-28 US US17/059,148 patent/US12318366B2/en active Active
- 2019-05-28 SI SI201930909T patent/SI3804714T1/en unknown
- 2019-05-28 DK DK19811377.1T patent/DK3804715T3/en active
- 2019-05-28 WO PCT/CN2019/088861 patent/WO2019228362A1/en active IP Right Grant
- 2019-05-28 MX MX2020012972A patent/MX2020012972A/en unknown
- 2019-05-28 BR BR112020024203-9A patent/BR112020024203A2/en unknown
- 2019-05-28 CA CA3101831A patent/CA3101831A1/en active Pending
- 2019-05-28 IL IL279036A patent/IL279036B2/en unknown
- 2019-05-28 US US17/058,883 patent/US11992477B2/en active Active
- 2019-05-28 KR KR1020207038034A patent/KR102695132B1/en active Active
- 2019-05-28 MX MX2020012966A patent/MX2020012966A/en unknown
- 2019-05-28 AU AU2019278013A patent/AU2019278013B2/en active Active
- 2019-05-28 CA CA3101826A patent/CA3101826A1/en active Pending
- 2019-05-28 SG SG11202011884QA patent/SG11202011884QA/en unknown
- 2019-05-28 RS RS20250231A patent/RS66565B1/en unknown
- 2019-05-28 KR KR1020207037631A patent/KR102695126B1/en active Active
- 2019-05-28 LT LTEPPCT/CN2019/088864T patent/LT3804715T/en unknown
- 2019-05-28 ES ES19810783T patent/ES3016532T3/en active Active
- 2019-05-28 HR HRP20250257TT patent/HRP20250257T1/en unknown
- 2019-05-28 CA CA3101825A patent/CA3101825A1/en active Pending
- 2019-05-28 KR KR1020247017725A patent/KR20240091095A/en not_active Abandoned
- 2019-05-28 WO PCT/CN2019/088862 patent/WO2019228363A1/en active Application Filing
- 2019-05-28 HR HRP20250268TT patent/HRP20250268T1/en unknown
- 2019-05-28 AU AU2019278015A patent/AU2019278015B2/en active Active
- 2019-05-28 MX MX2020012967A patent/MX2020012967A/en unknown
- 2019-05-28 SI SI201930907T patent/SI3804716T1/en unknown
- 2019-05-28 CN CN202111601610.3A patent/CN114246950A/en active Pending
- 2019-05-28 FI FIEP19811377.1T patent/FI3804715T3/en active
- 2019-05-28 CN CN201910453076.2A patent/CN110548146B/en active Active
- 2019-05-28 RS RS20250232A patent/RS66566B1/en unknown
- 2019-05-28 PT PT198116915T patent/PT3804716T/en unknown
- 2019-05-28 SG SG11202011886TA patent/SG11202011886TA/en unknown
- 2019-05-28 SM SM20250107T patent/SMT202500107T1/en unknown
- 2019-05-28 PL PL19810783.1T patent/PL3804714T3/en unknown
- 2019-05-28 EP EP19811691.5A patent/EP3804716B1/en active Active
- 2019-05-28 ES ES19811377T patent/ES3015131T3/en active Active
- 2019-05-28 AU AU2019278016A patent/AU2019278016B2/en active Active
- 2019-05-28 ES ES19811691T patent/ES3017250T3/en active Active
- 2019-05-28 CA CA3101832A patent/CA3101832A1/en active Pending
- 2019-05-28 PT PT198113771T patent/PT3804715T/en unknown
- 2019-05-28 WO PCT/CN2019/088863 patent/WO2019228364A1/en active Application Filing
- 2019-05-28 EP EP19812252.5A patent/EP3811939A4/en not_active Withdrawn
- 2019-05-28 JP JP2020566718A patent/JP7565589B2/en active Active
- 2019-05-28 US US17/058,903 patent/US11963947B2/en active Active
- 2019-05-28 US US17/058,863 patent/US11666556B2/en active Active
- 2019-05-28 CN CN202111601620.7A patent/CN114259491A/en active Pending
- 2019-05-28 AU AU2019278014A patent/AU2019278014B2/en active Active
- 2019-05-28 CA CA3101829A patent/CA3101829A1/en active Pending
- 2019-05-28 IL IL279039A patent/IL279039B2/en unknown
- 2019-05-28 JP JP2020566565A patent/JP2021525722A/en active Pending
- 2019-05-28 EP EP19810783.1A patent/EP3804714B1/en active Active
- 2019-05-28 WO PCT/CN2019/088866 patent/WO2019228367A1/en not_active Application Discontinuation
- 2019-05-28 AU AU2019278018A patent/AU2019278018B2/en active Active
- 2019-05-28 US US17/058,936 patent/US12064416B2/en active Active
- 2019-05-28 JP JP2020566564A patent/JP7479696B2/en active Active
- 2019-05-28 JP JP2020566720A patent/JP2021525741A/en active Pending
- 2019-05-28 CN CN201910453723.XA patent/CN110548026B/en active Active
- 2019-05-28 US US17/058,929 patent/US20210214312A1/en not_active Abandoned
- 2019-05-28 CN CN202111601625.XA patent/CN114010793B/en active Active
- 2019-05-28 CN CN202111599185.9A patent/CN114028574A/en active Pending
- 2019-05-28 MX MX2020012970A patent/MX2020012970A/en unknown
- 2019-05-28 HU HUE19811377A patent/HUE070297T2/en unknown
- 2019-05-28 IL IL279037A patent/IL279037B2/en unknown
- 2019-05-28 SM SM20250104T patent/SMT202500104T1/en unknown
- 2019-05-28 JP JP2020566675A patent/JP7265276B2/en active Active
- 2019-05-28 KR KR1020207037950A patent/KR102695130B1/en active Active
- 2019-05-28 PL PL19811691.5T patent/PL3804716T3/en unknown
- 2019-05-28 AU AU2019278017A patent/AU2019278017A1/en not_active Abandoned
- 2019-05-28 CN CN202111599339.4A patent/CN114209694A/en active Pending
- 2019-05-28 MX MX2020012965A patent/MX2020012965A/en unknown
- 2019-05-28 RS RS20250230A patent/RS66564B1/en unknown
- 2019-05-28 SM SM20250112T patent/SMT202500112T1/en unknown
- 2019-05-28 EP EP19810210.5A patent/EP3804712A4/en not_active Withdrawn
- 2019-05-28 HU HUE19811691A patent/HUE070298T2/en unknown
- 2019-05-28 BR BR112020024271-3A patent/BR112020024271A2/en unknown
- 2019-05-28 PL PL19811377.1T patent/PL3804715T3/en unknown
- 2019-05-28 FI FIEP19810783.1T patent/FI3804714T3/en active
- 2019-05-28 CN CN201910453079.6A patent/CN110548147B/en active Active
- 2019-05-28 RU RU2020143045A patent/RU2770775C1/en active
- 2019-05-28 CN CN202111599191.4A patent/CN114159570B/en active Active
- 2019-05-28 KR KR1020207037642A patent/KR102703153B1/en active Active
- 2019-05-28 DK DK19810783.1T patent/DK3804714T3/en active
- 2019-05-28 JP JP2020566710A patent/JP2021525739A/en active Pending
- 2019-05-28 LT LTEPPCT/CN2019/088861T patent/LT3804714T/en unknown
- 2019-05-28 PT PT198107831T patent/PT3804714T/en unknown
- 2019-05-31 TW TW108118936A patent/TWI764000B/en active
- 2019-05-31 TW TW108118939A patent/TWI706947B/en active
- 2019-05-31 TW TW108118940A patent/TWI778268B/en active
- 2019-05-31 TW TW108118896A patent/TWI761681B/en active
- 2019-05-31 TW TW108118901A patent/TWI794503B/en active
- 2019-05-31 TW TW108118937A patent/TWI765157B/en active
2020
- 2020-11-27 IL IL279034A patent/IL279034A/en unknown
- 2020-11-27 IL IL279040A patent/IL279040A/en unknown
- 2020-12-09 ZA ZA2020/07679A patent/ZA202007679B/en unknown
- 2020-12-09 ZA ZA2020/07687A patent/ZA202007687B/en unknown
- 2020-12-09 ZA ZA2020/07681A patent/ZA202007681B/en unknown
- 2020-12-09 ZA ZA2020/07688A patent/ZA202007688B/en unknown
- 2020-12-09 ZA ZA2020/07671A patent/ZA202007671B/en unknown
- 2020-12-09 ZA ZA2020/07678A patent/ZA202007678B/en unknown
2022
- 2022-11-07 JP JP2022178385A patent/JP2022190170A/en active Pending
- 2022-11-07 JP JP2022178239A patent/JP2022190161A/en active Pending
- 2022-11-07 JP JP2022178345A patent/JP2022190168A/en active Pending
- 2022-11-07 JP JP2022178201A patent/JP2022190159A/en active Pending
- 2022-11-07 JP JP2022178296A patent/JP2022190165A/en active Pending
- 2022-11-07 JP JP2022178269A patent/JP2022190162A/en active Pending
2023
- 2023-05-03 US US18/311,846 patent/US20230346748A1/en not_active Abandoned
2024
- 2024-03-19 US US18/610,100 patent/US20240299357A1/en active Pending

Also Published As

Publication number	Publication date
EP3804712A4 (en)	2022-05-25
JP2021525741A (en)	2021-09-27
SG11202011884QA (en)	2020-12-30
EP3804716A4 (en)	2022-05-25
JP2022190170A (en)	2022-12-22
JP2021525722A (en)	2021-09-27
IL279037B2 (en)	2025-01-01
MX2020012966A (en)	2021-02-16
CA3101831A1 (en)	2019-12-05
CN110548026B (en)	2022-01-14
MX2020012970A (en)	2021-02-16
DK3804716T3 (en)	2025-03-03
KR102703153B1 (en)	2024-09-06
CN110548148A (en)	2019-12-10
CN114209694A (en)	2022-03-22
KR20210016416A (en)	2021-02-15
FI3804714T3 (en)	2025-03-08
US20210214343A1 (en)	2021-07-15
JP2021525733A (en)	2021-09-27
MX2020012972A (en)	2021-02-16
SG11202011881PA (en)	2020-12-30
FI3804716T3 (en)	2025-03-08
DK3804715T3 (en)	2025-02-24
TWI764000B (en)	2022-05-11
CN110548147A (en)	2019-12-10
RS66564B1 (en)	2025-03-31
EP3804716A1 (en)	2021-04-14
SG11202011893UA (en)	2020-12-30
WO2019228364A1 (en)	2019-12-05
JP2021535893A (en)	2021-12-23
TWI778268B (en)	2022-09-21
TW202003501A (en)	2020-01-16
EP3804714B1 (en)	2024-12-25
SMT202500107T1 (en)	2025-05-12
CA3101825A1 (en)	2019-12-05
AU2019278013A1 (en)	2021-01-21
BR112020024107A2 (en)	2021-02-17
MX2020012969A (en)	2021-02-16
KR102695135B1 (en)	2024-08-16
MX2020012965A (en)	2021-02-16
LT3804714T (en)	2025-03-10
RU2770043C1 (en)	2022-04-14
SG11202011888VA (en)	2020-12-30
DK3804714T3 (en)	2025-03-03
HRP20250258T1 (en)	2025-05-09
WO2019228362A1 (en)	2019-12-05
AU2019278018A1 (en)	2021-01-21
TW202003500A (en)	2020-01-16
CN110548027B (en)	2022-01-14
JP2022190162A (en)	2022-12-22
CN110548146B (en)	2022-01-14
AU2019278015A1 (en)	2021-01-07
WO2019228366A1 (en)	2019-12-05
CN114259491A (en)	2022-04-01
EP3804714A1 (en)	2021-04-14
JP2022190168A (en)	2022-12-22
US20210220334A1 (en)	2021-07-22
CA3101822C (en)	2024-05-21
LT3804716T (en)	2025-03-25
ZA202007681B (en)	2024-06-26
TW202003464A (en)	2020-01-16
CN114246950A (en)	2022-03-29
IL279037B1 (en)	2024-09-01
RU2770775C1 (en)	2022-04-21
AU2019278017A1 (en)	2021-01-21
JP2021525739A (en)	2021-09-27
EP3804715B1 (en)	2024-12-25
HUE070298T2 (en)	2025-05-28
BR112020024348A2 (en)	2021-02-23
KR102695126B1 (en)	2024-08-16
TW202003498A (en)	2020-01-16
US20210196683A1 (en)	2021-07-01
CN110548147B (en)	2022-01-14
JP2022190159A (en)	2022-12-22
ES3015131T3 (en)	2025-04-29
JP7265276B2 (en)	2023-04-26
CA3101832A1 (en)	2019-12-05
CN114010793B (en)	2025-04-25
JP2021525721A (en)	2021-09-27
ES3016532T3 (en)	2025-05-09
AU2019278013B2 (en)	2025-01-16
CN114159570A (en)	2022-03-11
PL3804714T3 (en)	2025-06-09
AU2019278018B2 (en)	2024-10-10
WO2019228365A1 (en)	2019-12-05
US11963947B2 (en)	2024-04-23
ES3017250T3 (en)	2025-05-12
HRP20250257T1 (en)	2025-04-11
AU2019278015B2 (en)	2024-10-03
PT3804716T (en)	2025-03-05
IL279039A (en)	2021-01-31
IL279039B1 (en)	2025-03-01
TWI765157B (en)	2022-05-21
FI3804715T3 (en)	2025-03-06
ZA202007688B (en)	2024-07-31
IL279040A (en)	2021-01-31
ZA202007687B (en)	2024-07-31
KR102695130B1 (en)	2024-08-16
US20210214312A1 (en)	2021-07-15
CN110548146A (en)	2019-12-10
AU2019278016B2 (en)	2024-10-10
WO2019228363A1 (en)	2019-12-05
BR112020024125A2 (en)	2021-02-17
CN114010793A (en)	2022-02-08
US20240299357A1 (en)	2024-09-12
EP3804714A4 (en)	2022-05-25
PL3804715T3 (en)	2025-03-31
EP3804712A1 (en)	2021-04-14
MX2020012967A (en)	2021-02-16
EP3811939A4 (en)	2022-05-25
ZA202007671B (en)	2024-05-30
IL279039B2 (en)	2025-07-01
RS66566B1 (en)	2025-03-31
US12064416B2 (en)	2024-08-20
EP3804716B1 (en)	2024-12-25
EP3804713A1 (en)	2021-04-14
IL279035B2 (en)	2025-01-01
CN114159570B (en)	2025-06-27
WO2019228367A1 (en)	2019-12-05
AU2019278016A1 (en)	2021-01-21
JP2022190165A (en)	2022-12-22
IL279035A (en)	2021-01-31
KR20210016436A (en)	2021-02-15
US20230346748A1 (en)	2023-11-02
ZA202007678B (en)	2024-06-26
US11666556B2 (en)	2023-06-06
CN110548027A (en)	2019-12-10
HRP20250268T1 (en)	2025-04-25
JP7565589B2 (en)	2024-10-11
HUE070297T2 (en)	2025-05-28
CA3101822A1 (en)	2019-12-05
SMT202500112T1 (en)	2025-05-12
US20210212991A1 (en)	2021-07-15
CN114028574A (en)	2022-02-11
HUE070296T2 (en)	2025-05-28
US20210196682A1 (en)	2021-07-01
EP3811939A1 (en)	2021-04-28
AU2019278014B2 (en)	2024-10-31
BR112020024269A2 (en)	2021-02-23
ZA202007679B (en)	2024-08-28
BR112020024203A2 (en)	2021-02-17
PT3804714T (en)	2025-03-10
TW202003499A (en)	2020-01-16
KR20210016437A (en)	2021-02-15
IL279036B1 (en)	2025-03-01
CA3101826A1 (en)	2019-12-05
PL3804716T3 (en)	2025-04-28
KR20210014168A (en)	2021-02-08
KR20210016421A (en)	2021-02-15
TWI761681B (en)	2022-04-21
IL279034A (en)	2021-01-31
PT3804715T (en)	2025-02-25
US11992477B2 (en)	2024-05-28
KR102695132B1 (en)	2024-08-14
SI3804716T1 (en)	2025-04-30
TWI794503B (en)	2023-03-01
SMT202500104T1 (en)	2025-05-12
EP3804713A4 (en)	2022-03-02
BR112020024271A2 (en)	2021-02-23
CN110548026A (en)	2019-12-10
TWI706947B (en)	2020-10-11
CN110548149A (en)	2019-12-10
SI3804715T1 (en)	2025-04-30
CN110548149B (en)	2022-01-14
IL279035B1 (en)	2024-09-01
TW202003502A (en)	2020-01-16
SI3804714T1 (en)	2025-04-30
EP3804715A4 (en)	2022-05-25
CA3101829A1 (en)	2019-12-05
CN110548148B (en)	2022-01-14
KR20240091095A (en)	2024-06-21
EP3804715A1 (en)	2021-04-14
US12318366B2 (en)	2025-06-03
JP2022190161A (en)	2022-12-22
LT3804715T (en)	2025-03-25
IL279036A (en)	2021-01-31
SG11202011883RA (en)	2020-12-30
IL279037A (en)	2021-01-31
KR20210016420A (en)	2021-02-15
IL279036B2 (en)	2025-07-01
RS66565B1 (en)	2025-03-31
AU2019278014A1 (en)	2021-01-21
JP7479696B2 (en)	2024-05-09

Publication	Publication Date	Title
SG11202011886TA (en)	2020-12-30	PHARMACEUTICAL COMBINATION, COMPOSITION AND FORMULATION CONTAINING GLUCOKINASE ACTIVATOR AND a-GLUCOSIDASE INHIBITOR, PREPARATION METHODS THEREFOR AND USES THEREOF
EP3706741A4 (en)	2022-03-30	Pharmaceutical composition and use thereof
EP3673897A4 (en)	2021-05-05	Injectable pharmaceutical composition containing meloxicam, and preparation method therefor
EP3891148A4 (en)	2022-09-07	Ret inhibitors, pharmaceutical compositions and uses thereof
EP3697411A4 (en)	2021-08-18	Novel pharmaceutical composition and use thereof
EP3770148A4 (en)	2022-01-05	Receptor inhibitor, pharmaceutical composition comprising same, and use thereof
EP3456711A4 (en)	2019-10-16	Caspase inhibitor and pharmaceutical composition, use and therapeutic method thereof
MX2018014790A (en)	2019-04-25	Combination formulation of three antiviral compounds.
EP3733670A4 (en)	2022-01-26	Tetrahydropyrrole compound, preparation method therefor, pharmaceutical composition containing same, and use thereof
IL284132A (en)	2021-08-31	Pharmaceutical compound, the method of its making and use as medicinal agent
EP3210614A4 (en)	2018-06-13	Composition containing thymosin beta 4, and pharmaceutical formulation comprising same
EP3718543A4 (en)	2021-07-21	Pharmaceutical composition and use thereof
HK40029777B (en)	2024-03-08	Receptor inhibitor, pharmaceutical composition comprising same, and use thereof
HK40060139A (en)	2022-05-13	Ret inhibitors, pharmaceutical compositions and uses thereof
HK40060141A (en)	2022-05-13	Ret inhibitors, pharmaceutical compositions and uses thereof
SG11202010069SA (en)	2020-11-27	Dipeptide and pharmaceutical composition containing same